Vanderbilt Health is conducting a research study that will look at whether plasma administered early in the course of treatment helps severely burned patients survive their injuries.
The “Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury” (PREEVEnT) trial will include approximately 750 people ages 18 to 75. Patients who have severe thermal burn injuries covering at least 20% of their total body surface may be enrolled by participating emergency medical personnel after arrival at Vanderbilt Health.
PREEVEnT is an Exception from Informed Consent (EFIC) trial, meaning that the trial requires performing a potentially lifesaving intervention in people who are too injured to give permission. This study will look at treatment for patients who have a severe thermal burn injury and will be admitted to the burn intensive care unit. These patients are too injured to give permission before receiving the study drug. Permission for continued participation will be obtained from patients once they are able, or from their family members, as soon as possible.
For more information about PREEVEnT or to complete an anonymous survey about this EFIC study, please go to www.litesnetwork.org/PREEVEnT.
This research is supported by Department of Defense contract award No. HT9425-24-F-0322. Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the U.S. Army, Department of Defense or U.S. government.
